다낭성난소증후군 환자의 체외수정시술에서 Rosiglitazone이 난소기질혈류와 난소반응 및 체외수정결과에 미치는 영향
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
=목적: 다낭성난소증후군 환자에서 rosiglitazone이 난소기질혈류와 난소반응 및 체외수정결과에 미치는 영향을 연구하고자 한다. 연구 방법: 다낭성난소증후군이면서 그 외의 불임인자로는 난관인자만 존재하는 24-36세의 불임여성 46명을 대상으로 하여 무작위적으로 rosiglitazone군 (23명)과 대조군 (23명)으로 나누었다. 실험군은 GnRH agonist 투여 전, 생리주기 제1일째부터 4 mg의 rosiglitazone을 하루 1회 투여하였고, 이를 hCG 투여날까지 지속하였다. 대조군에서는 위약을 같은 기간동안 투여하였으며 양 군은 각각 23주기의 체외수정시술을 시행받았다. 모든 환자는 난소기질혈류를 알기 위해 질식 색초음파 분석 (resistance index (RI) and pulsatility index (PI))을 rosiglitazone이나 위약을 투여하기 시작한 날 (RI0, PI0), GnRH agonist 투여날 (RI1, PI1), 그리고 난소자극을 시작한 날 (RI2, PI2)에 각각 측정하였다. 결과: 환자의 연령, 체질량지수, 불임기간, 내분비적 호르몬 수치, 공복 및 75 g 당부하 2시간 후 혈당수치와 난소기질동맥의 RI0, PI0 값은 양군간에 차이가 없었다. RI1과 PI1 값은 실험군에서 보다 높은 값을 보였으나 통계적으로 유의성은 없었다. RI2와 PI2 값은 실험군에서 대조군보다 유의하게 높았다 (0.60±0.04 versus 0.56±0.03; P<0.05, 0.99±0.14 versus 0.88±0.05; P<0.01). hCG 투여날, 10-14 mm 크기의 난포수 및 14 mm 이상의 난포수와 회수된 난자수는 실험군에서 유의하게 적었다 (P<0.05, P<0.05). 임상적 임신율은 실험군에서 높았으나 통계적 유의성에는 도달하지 못했다.
참고문헌 (29)
- "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome", 81, pp.19~25 (2004)
- "Insulin resistance and the polycystic ovary syndrome:mechanism and implications for pathogenesis", 18, pp.774~800 (1997)
- "Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion", 16, pp.322~353 (1995)
- "Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovarian syndrome", 61, pp.946~51 (1985)
- "Coronary heart disease risk factors in women with polycystic ovarian syndrome", 15, pp.821~826 (1995)
- "Prevalence and predictors of dyslipidemia in women with polycystic syndrome", 111, pp.607~613 (2001)
- "Regulation of androgen production in cultured human thecal cells by insulin-like growth factor and insulin", 59, pp.323~5 (1993)
- "Metabolic regulation of androgen production by human theca cells in vitro", 10, pp.75~81 (1995)
- "Effects of metformin on spontaneous and clomiphene induced ovulation in PCOS", 338, pp.1876~1880 (1995)
- "Troglitazone-induced liver failure:a case study", 114, pp.299~306 (2003)
- "Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone", 76, pp.1057~1059 (2001)
- "Ovarian stromal blood flow changes in women with polycystic ovaries. A possible new marker for ultrasound diagnosis?", 10, pp.1992~1996 (1995)
- "Blood flow change in the ovarian and uterine arteries in women with polycystic ovary syndrome who respond to clomiphene citrate:correlation with serum hormone concentration Ultrasound Obstet", 12, pp.188~196 (1998)
- "Color doppler analysis in oligo and ammenorrheic women with polycystic ovary syndrome", 11, pp.105~110 (1999)
- "Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries", 13, pp.651~655 (1998)
- "What is polycystic ovary syndrome? Are national views important?Are national views important?", 17, pp.2219~2227 (2002)
- "What is polycystic ovary syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovary syndrome", 17, pp.2495~2499 (2002)
- "Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome", 22, pp.141~146 (1999)
- "Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications", 15, pp.111~122 (1997)
- "Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus", 338, pp.867~872 (1998)
- "Effects of metformin on insulin secretion and ovarian steroidogenesis in women with polycystic ovary syndrome", 82, pp.524~530 (1997)
- "Metformin improves insulin resistance in type I", pp.923~5
- "Metformin reduces requirement in type I diabetes", 24, pp.351~354 (1998)
- "Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovarian syndrome who are resistant to clomiphene citrate alone", 75, pp.310~315 (2001)
- "Effective metformin on spontaneous and clomiphene induced ovulation in PCOS", 338, pp.1876~1880 (1998)
- "Activators of peroxisome proliferator-activated receptor have depot-specific effects on human preadipocyte differentiation", 100, pp.3149~3153 (1997)
- "Troglitazone improves ovulation and hirsutism in the polycystic ovarian syndrome: a multicenter, double-blind, placebo-controlled trial", 86, pp.1626~1632 (2001)
- "Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome", 71, pp.323~327 (1999)
- "a new class of antidiabetic drug"
